Ipsen
IPN
ISIN FR0010259150 / Valor 2348805
Ipsen
UMushroom community rating:
About company
Ipsen is a mid-sized global biopharmaceutical company that has been working in oncology since 1986. The company's portfolio includes treatments for various types of cancers, such as neuroendocrine tumor (NETs), kidney, liver, pancreas, thyroid, prostate, and breast cancer. Ipsen is dedicated to improving patients' lives through research, innovation, and the development of transformative medicines in Oncology, Rare Disease, and Neuroscience. The company also has ambitious goals in terms of ESG responsibility, focusing on Environment, Patients, People, and Governance as part of its Generation Ipsen strategy.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (23.10.2025):
Ipsen reported strong sales for the first nine months of 2025 in Q3 2025 and has upgraded its full-year guidance.
Sales Performance
The company achieved robust growth across all three therapeutic areas, with significant expansion in its rare liver disease franchise.
Full-Year Guidance
Building on the strong sales momentum, Ipsen has raised its financial outlook for the entire year of 2025.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
12514 M
Market cap (USD)
69,602
Daily traded volume (Shares)
110.8 / 109.9
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
